Document Detail


Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells.
MedLine Citation:
PMID:  20371712     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
MDM2 is an E3 ubiquitin ligase that binds and ubiquitinates the tumor suppressor protein p53, leading to its proteasomal degradation. Nutlin-3a (Nutlin) is a preclinical drug that binds MDM2 and prevents the interaction between MDM2 and p53, leading to p53 stabilization and activation of p53 signaling events. Previous studies have reported that Nutlin promotes growth arrest and/or apoptosis in cancer cells that express wild-type p53. In the current study, Nutlin treatment caused a cytoskeletal rearrangement in p53 wild-type human cancer cells from multiple etiologies. Specifically, Nutlin decreased actin stress fibers and reduced the size and number of focal adhesions in treated cells. This process was dependent on p53 expression but was independent of p21 expression and growth arrest. Consistent with this, Nutlin-treated cells failed to form filamentous actin-based motility structures (lamellipodia) and displayed significantly decreased directional persistence in response to migratory cues. Finally, chemotactic assays showed a p53-dependent/p21-independent decrease in migratory and invasive capacity of Nutlin-treated cells. Taken together, these findings reveal that Nutlin treatment can inhibit the migration and invasion capacity of p53 wild-type cells, adding to the potential therapeutic benefit of Nutlin and other small molecule MDM2 inhibitors. Mol Cancer Ther; 9(4); 895-905. (c)2010 AACR.
Authors:
Diarmuid M Moran; Carl G Maki
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2010-04-06
Journal Detail:
Title:  Molecular cancer therapeutics     Volume:  9     ISSN:  1538-8514     ISO Abbreviation:  Mol. Cancer Ther.     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-04-09     Completed Date:  2010-07-07     Revised Date:  2014-09-13    
Medline Journal Info:
Nlm Unique ID:  101132535     Medline TA:  Mol Cancer Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  895-905     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Actins / metabolism
Cell Line, Tumor
Cell Movement / drug effects*
Cyclin-Dependent Kinase Inhibitor p21 / metabolism
Cytoskeleton / drug effects*,  metabolism*
Focal Adhesions / drug effects,  metabolism
Humans
Imidazoles / pharmacology*
Neoplasm Invasiveness
Piperazines / pharmacology*
Pseudopodia / drug effects,  metabolism
Stress Fibers / drug effects,  metabolism
Tumor Suppressor Protein p53 / metabolism*
Grant Support
ID/Acronym/Agency:
1R01CA137598-01A1/CA/NCI NIH HHS; R01 CA108843/CA/NCI NIH HHS; R01 CA108843-05/CA/NCI NIH HHS; R01 CA137598/CA/NCI NIH HHS; R01 CA137598-01A1/CA/NCI NIH HHS; R01CA108843/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Actins; 0/Cyclin-Dependent Kinase Inhibitor p21; 0/Imidazoles; 0/Piperazines; 0/Tumor Suppressor Protein p53; 0/nutlin 3
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation p...
Next Document:  Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800.